CareDx, Inc (CDNA)
| Market Cap | 525.30M |
| Revenue (ttm) | 297.14M |
| Net Income (ttm) | -90.52M |
| Shares Out | 54.10M |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,185,686 |
| Open | 9.87 |
| Previous Close | 9.76 |
| Day's Range | 9.65 - 10.12 |
| 52-Week Range | 4.80 - 18.04 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 13.80 (+42.12%) |
| Earnings Date | Nov 8, 2023 |
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence sp... [Read more]
Financial Performance
In 2022, CareDx's revenue was $321.79 million, an increase of 8.57% compared to the previous year's $296.40 million. Losses were -$76.61 million, 149.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $13.8, which is an increase of 42.12% from the latest price.
News
CareDx Reports Third Quarter 2023 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx to Report Third Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Announces CEO Transition
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.'s (NASDAQ: CDNA)...
US Supreme Court rebuffs CareDx patent lawsuit over organ-rejection tests
The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by Natera and Eurofins Viracor , turning down another request to revisit the contentious issue of ...
CareDx To Present at the 2023 Cantor Global Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Reports Second Quarter 2023 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx to Report Second Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx's HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx's AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...
CareDx Reports First Quarter 2023 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx to Report First Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-val...